Abstract Arginine vasopressin (AVP) is the major physiological regulator of renal water excretion and blood volume. The AVP pathways of V 1a R-mediated vasoconstriction and V 2 R-induced water retention represent a potentially attractive target of therapy for edematous diseases. Experimental and clinical evidence suggests beneficial effects of AVP receptor antagonists by increasing free water excretion and serum sodium levels. This review provides an update on the therapeutic implication of newly developed AVP receptor antagonists in respective disorders, such as chronic heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion.
Introduction
Arginine vasopressin (AVP), also known as antidiuretic hormone, is the major physiological regulator of renal water excretion and blood volume. AVP is synthesized in the neurosecretory cells of the supraoptic and paraventricular nuclei of the hypothalamus and stored in neurosecretory granules in the posterior pituitary gland. Although increased plasma osmolality is the major regulator of AVP release [1, 2] , AVP can be released upon both osmotic and non-osmotic stimulation (Fig. 1) . Osmoreceptors with an extraordinary high sensitivity to changes in plasma osmolality reside in the hypothalamus. Thus, an increase of only 1% in plasma osmolality induces AVP release into the circulatory system [2] . The osmotic threshold for AVP secretion is approximately 280 mmol/kg [3] and can be modified under certain circumstances, such as changes in blood pressure or in circulatory blood volume, or by pregnancy. A decrease of 5-7% in mean arterial pressure or a reduction of 8-10% in plasma volume are generally sufficient to trigger detectable increases in AVP serum levels [4] . An increase in AVP secretion leads to thirst with consecutive increased water intake and antidiuresis, both resulting in an increased arterial circulating volume and decreased plasma osmolality.
AVP actions are mediated by at least three different Gprotein-coupled receptors called V 1a , V 1b (also known as V 3 ), and V 2 (Fig. 2) . The V 1a receptor (V 1a R), abundantly expressed in vascular smooth muscle cells, hepatocytes and platelets, and the V 1b receptor (V 1b R), predominantly found in the anterior pituitary gland, are linked to the phosphoinositol signalling pathway with intracellular calcium as second messenger. In contrast, the V 2 receptor (V 2 R) is coupled to adenylate cyclase signalling with intracellular cAMP as the second messenger. V 2 R has long been thought to be exclusively expressed in renal tubules [5] , but there is increasing evidence of extrarenal V 2 R expression [6] [7] [8] . V 1a R mediates vasoconstrictive effects, while V 2 R regulates water re-absorption in the renal collecting ducts. Stimulation of this receptor induces an intracellullar cascade that promotes trafficking of preformed aquaporin 2 (AQP2) water channels from the cytosol to the apical plasma membrane [9] . The physiologic role of the V 3 R is not completely understood, and it is presumed to be involved in corticotropin and glucagon release [10, 11] in addition to cellular proliferation and differentiation effects [12] .
Dysregulation of this meticulously controlled feedback system in edematous diseases is mainly caused by sustained or even increased AVP secretion despite hypoosmolality. A low effective circulating blood volume, as in chronic heart failure (CHF), advanced liver cirrhosis or volume depletion activates baroreceptors in the carotid sinus, aortic arch and the left atrium, and this stimulus for AVP secretion overrides osmotic signals, resulting in hyponatremia as a part of the compensatory responses [13] . Persistent AVP secretion may also occur in tumor cells, which is one cause of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). A wide range of substances involving a neurohormonal antagonism has been developed with the aim of alleviating congestion and improving hemodynamics both acutely and chronically. This review discusses therapeutic implications of newly developed AVP receptor antagonists in CHF, liver cirrhosis and SIADH based on the latest available clinical data.
Pathogenesis of water retention in heart failure
The pathophysiology of CHF is complex and involves the interplay of multiple neurohumoral and cellular systems. The decrease in left ventricular (LV) systolic and diastolic function results in reduced cardiac output, stroke volume and intraarterial blood volume. Arterial underfilling, sensed by arterial baroreceptors in the aortic arch and intrarenal sensors, leads to the subsequent activation of the sympathoadrenal system and release of a cascade of neurohormones aimed at correcting the arterial hypovolemia and restoration of organ perfusion. Early compensatory mechanisms include vasoconstrictive and sodium retentive actions mediated by the reninangiotensin-aldosterone system (RAAS), the sympathetic nervous system, AVP, thromboxane and endothelin [14] [15] [16] . These sodium-and volume-retaining mechanisms are counter-balanced by the enhancement of the vasodilatory, natriuretic hormonal or cytokine systems, including the natriuretic peptides, prostaglandins, bradykinin and nitric oxide [17, 18] . Initially, these important compensatory mechanisms act to maintain blood pressure and adequate tissue perfusion [19] . However, prolonged activation of these systems, such as in patients with CHF, leads to a vicious cycle of hemodynamic alterations, which ultimately deleteriously affects cardiac and renal function.
Diuretics are currently the most widely used therapy in CHF to reduce fluid overload. While rapid symptomatic improvement and a decrease in volume overload are observed with diuretic therapy, especially for acute decompensated CHF (ADHF), therapy with diuretics is associated with several adverse effects, such as increased neurohormonal activation, worsening renal function and electrolyte disturbances [20, 21] .
Although patients with CHF are hypervolemic with lower plasma osmolality and serum sodium levels, AVP serum levels are elevated in CHF due to the lower effective arterial blood volume, decreased cardiac output and angiotensin II-induced AVP release. Indeed, the serum AVP level is a prognostic parameter and correlates with the severity of cardiac impairment [22, 23] . AVP exerts adverse effects in CHF by increasing peripheral resistance via V 1a R -mediated vasoconstriction and by enhancing water retention through effects on the renal V 2 R [24, 25] . Furthermore, sustained stimulation of V 1a R in the heart can lead to remodelling by stimulating cell hypertrophy [26] and further deteriorates cardiac function (Fig. 3) . Therefore, blockade of the AVP system may prove to be a useful adjunct or alternative to standard therapy in CHF.
Pathogenesis of water retention in liver cirrhosis
Similar to the compensatory mechanisms in CHF, the aim of activation of neurohumoral systems in liver cirrhosis is to preserve circulatory homeostasis and to maintain arterial pressure. Impairment of water excretion is a common feature of patients with liver cirrhosis, with up to 75% of patients with cirrhosis having an impaired free water clearance after a water load [27] . In its early stage, liver cirrhosis is characterized by peripheral vasodilatation and splanchnic venous pooling, which in turn will result in a decreased vascular resistance. The arterial underfilling leads to a non-osmotic baroreceptor-triggered AVP release and water retention, followed by dilutional hyponatremia [28] . Secondary to the arterial vasodilatation is the activation of the sympathetic system. Arterial underfilling is a strong stimulus for the sympathetic nervous system and, via β-adrenergic stimulation, this in turn results in activation of the RAAS and renal sodium retention. Angiotensin activates receptors in the proximal tubule epithelium, enhancing sodium reabsorption and impairment of the normal feedback mechanism via aldosterone in the distal nephron.
Bichet et al. studied the AVP response in cirrhotic patients to a standard water load [29] . There was a significant difference in the AVP response between those patients excreting more than 80% of their water load within 5 h and those with impaired excretion of the water load who were unable to suppress AVP secretion adequately. Furthermore, significantly higher levels of norepinephrine, renin activity and aldosterone in nonsecreting patients were shown, indicating that increased sympathetic activity, as assessed by plasma levels of norepinephrine, correlates closely with sodium and water retention in cirrhotic patients and thus may be of pathogenetic importance [30] . There is growing evidence linking adverse outcome to increased AVP levels in liver cirrhosis, reflecting the severity of the disease [28] . Plasma sodium concentrations of <130 meq/ l in cirrhosis are associated with a median transplant-free survival of <6 months [31] . In addition, hyponatremia can cause neurological disturbances, which contribute to the overall morbidity of these patients.
Water retention therapy in liver cirrhosis consists in water and sodium restriction as well as in the application of loop diuretics to induce natriuresis and spironolactone to overcome the effects of hyperaldosteronism. New strategies in the therapy of water retention and hyponatremia in liver cirrhosis include vaptans and the possibility of combining diuretics with new drugs in order to achieve a better control of ascites, without increasing the risk of side-effects.
Pathogenesis of SIADH
Hyponatremia is frequently found in hospitalized patients. Clinical assessment of volume status in addition to urine and blood osmolality analysis often allows the clinician to differentiate between hypervolemic and euvolemic hyponatremia (Fig. 4) .
Hyponatremia due to SIADH is common and the causes of SIADH are manifold [32] . SIADH is characterized by the following features: hypotonic hypoosmolality with an osmolality <275 mosm/l; inappropriate high urine osmolality >100 mosm/l; increased natriuresis <40 mmol/l; euvolemia. Binding of AVP to the V2-receptor at the collecting duct leads to phosphorylation of AQP-2. Phosphorylated AQP-2 is then inserted in the apical plasma membrane and contributes to the re-absorption of free water. Despite hypotonicity, patients with SIADH continue to drink because the negative feedback loop is too weak to suppress their thirst [33] . In summary, total body water increases and dilutional hyponatremia develops. A common cause of SIADH (80% of patients) is ectopic hormone production by cancer, such as oat cell carcinoma of the lung [34] .In one study, 19.5% of patients with study-defined hyponatremia died during hospitalization, compared with 6.3% of the entire cancer population [32] .
Other causes of SIADH are neurological surgery, trauma, pulmonary, endocrine and neurologic diseases. A wide range of drugs, including antiinflammatory drugs, tricyclic antidepressants, serotonin-selective reuptake inhibitors and some antineoplastic agents, may also cause SIADH [35] [36] [37] . In contrast to hyponatremia in CHF or liver cirrhosis, hyponatremia in SIADH is typically associated with higher urine sodium concentrations (Fig. 4) .
Taken together, the hyponatremia in CHF, liver cirrhosis and SIADH is thought to stem from a decrease in effective arterial volume, which triggers baroreceptor activation and increases sympathetic activity, aldosterone secretion, sodium retention and AVP release, resulting in water retention and dilution of total body sodium.
Vasopressin receptor antagonists
The first AVP peptide antagonists were described in the 1970s by Mannig and Sawyer [38] . Despite the recognized antagonistic effects of these molecules in animals, their use in the therapy of edematous disease was hampered by marked species differences, partial agonist actions, poor bioavailability and short half-life. As a result of subsequent developmental research, the first non-peptide V 2 R antagonist was characterized by Yamamura in 1992 [39] . The nonpeptide antagonists are orally active and appear to be more bioavailable with longer half-lives than the earlier peptide substances. Several non-peptide AVP receptor antagonists, also known as "vaptans", have been developed and studied in human clinical trials. These vaptans include the dual V 1a / V 2 R antagonist conivaptan and the specific V 2 R antagonists tolvaptan, lixivaptan and satavaptan. The pharmacological properties and chemical structures of these compounds are outlined in Table 1 and Fig. 5 . Some of these drugs are now in clinical use, mainly for the treatment of euvolemic or hypervolemic hyponatremia and for water retentive states, such as cirrhosis or CHF. In this review we will summarize available clinical data on the most extensively studied vaptans (tolvaptan, conivaptan, lixivaptan and satavaptan) with their potential application in CHF, liver cirrhosis and SIADH (Table 2 ).
V 2 R antagonists

Tolvaptan
Tolvaptan is an oral, selective non-peptide vasopressin V 2 R antagonist without intrinsic agonist properties. In in vitro studies, tolvaptan was found to block the binding of AVP to cloned human V 2 R and V 1a R with an inhibition constant (K I ) of 0.43 and 12.3 nM, respectively, showing higher V 2 R-selectivity [40] .
The usual dosage for the approved indications is 15 mg daily and should be initiated in hospital; the maximum dosage should not exceed 60 mg once daily. Generally, no dosage adjustments are necessary in patients with hepatic or renal (creatinine clearance rate ≥10 ml/min) impairments. Tolvaptan should not be used in hypovolemic hyponatremia and is contraindicated in anuric patients.
Tolvaptan has linear pharmacokinetics and is primarily metabolized by cytochrome P450 3A4 (CYP3A4) [41] . Although the results of clinical studies have shown that Differentiation between euvolemic and hypervolemic hyponatremia. Hyponatremia is classified into three major categories based on plasma osmolality: normotone, hypertone and hypotone. A urine osmolality >100 mosm/l along with diminished urine sodium excretion (<20 mmol/l) is typically found in patients with liver cirrhosis or chronic heart failure (CHF). In contrast, patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) exhibit hyperosmolar urine with a higher (>40 mmol/l) urine sodium concentration tolvaptan is safe and well tolerated in humans, tolvaptan has the potential for a number of clinically relevant drug interactions, particularly when used in combination with CYP3A inhibitors. Less than 1% of the substance is eliminated unchanged via the urine [42] . In a human trial, increases in tolvaptan concentrations (C max ) were less than dose-proportional and plateaued at doses >240 mg [43] . The most frequent adverse events reported in clinical trials are thirst, frequent urination and dry mouth [44] .
CHF Tolvaptan has extensively been characterized in patients with CHF. In a double-blind, placebo-controlled study involving 254 patients with New York Heart Association (NYHA) class II or III CHF, tolvaptan added to standard therapy including non-potassium-sparing diuretics resulted in a significant decrease in body weight in the 30, 45 and 60 mg tolvaptan groups (−0.79±0.99, −0.96±0.93, and −0.84±0.02 kg, respectively; p<0.001 for all treatment groups vs. placebo), a normalization of serum sodium and an increase in urine volume (3.9±0.6, 4.2±0.9, 4.6±0.4 and 2.3±0.2 l/24 h, respectively; p <0.001) at day 1 without causing hypokalemia or worsening renal function [45] . The short-and intermediate-term effects of tolvaptan were further examined in the ACTIV in CHF trial [46] . In this trial, 319 patients hospitalized with CHF were randomized to treatments of 30, 60, 90 mg/day tolvaptan or placebo for up to 60 days in addition to the standard therapy. The primary inpatient outcome was change in body weight at 24 h after the administration of the first dose of the study drug. The primary outpatient endpoint was worsening CHF at 60 days after randomization, defined as mortality or hospitalization for CHF. The administration of tolvaptan resulted in a greater, non-dose-dependent, net volume reduction compared with placebo and Conivaptan Lixivaptan Tolvaptan Satavaptan for the three tolvaptan groups vs. placebo). Furthermore, tolvaptan produced a rapid and sustained increase of serum sodium levels in patients with hyponatremia. There were no significant differences in the second primary endpoint at 60 days in patients receiving tolvaptan compared with placebo. The post hoc analysis revealed a lower 60-day mortality rate in patients with severe renal dysfunction or systemic congestion. The latter finding in particular suggested a favorable effect of tolvaptan on hemodynamic parameters in CHF, which was further examined in the METEOR study [47] . The objective of this trial was to test the effects of intermediate-term therapy with tolvaptan on both LV dilatation and function (remodelling) and also on safety and tolerability in patients with CHF and LV systolic dysfunction. Eligible patients (n = 240) with mild-tomoderate CHF (NYHA II or III) and LV ejection fraction (LVEF) ≤30% were randomized to tolvaptan 30 mg/day or placebo. However, no significant effect of tolvaptan therapy was seen on LV volume or LVEF after 1 year of therapy.
The clinical applicability of tolvaptan was further evaluated in a pivotal EVEREST trial program [48] . The prospective, multicenter, double-blind, placebo-controlled EVEREST studies tested the benefit of single-dose tolvaptan (30 mg/day) versus placebo in three clinical trials: two short-term trials and a longer term safety and outcome trial. A total of 4133 patients with systolic dysfunction (LVEF <40%, NYHA III/IV) and hospitalized for ADHF CHF were randomized. The primary endpoint of the shortterm trials was a composite of changes in patient-assessed global clinical status and body weight at 7 days or the day of discharge from hospital. The primary endpoints of the longer term trial were all-cause mortality, cardiovascular death or CHF hospitalization. In both short-term trials, the addition of tolvaptan to standard therapy resulted in a significant improvement of global clinical status and body weight change at day 7 or at discharge. When the composite outcomes were considered individually (as secondary outcomes), there was a statistically demonstrable benefit for tolvaptan-induced reductions in body weight in both trials on day 1 and day 7 (p<0.001 for all comparisons). There were no significant differences in patient-assessed global clinical status in either trial.
The longer term trial demonstrated no differences in allcause mortality, cardiovascular death or CHF-related hospitalization between the groups. In the subgroup of patients with hyponatremia (serum sodium <134 mmol/l) at baseline, there was a significantly greater increase in mean serum sodium levels from baseline to day 7 in the tolvaptan group than in the placebo group (increase of 5.49 mmol/l vs. 1.85 mmol/l; p<0.001). This effect was maintained through 40 weeks of treatment.
Overall, the findings from the EVEREST trial demonstrate that tolvaptan produced an early and sustainable decrease in body weight in those patients hospitalized with worsening CHF and LVEF <30%, ameliorated dyspnea and edema and improved serum sodium in hyponatremic patients. Tolvaptan had no effect on global clinical condition, post-discharge mortality and hospitalization without evidence of harm.
In the following ECLIPSE study, a total of 181 patients with advanced CHF [NYHA class III/IV CHF, LVEF <40% and pulmonary capillary wedge pressure (PCWP) >18 mmHg] were randomized to double-blind treatment with tolvaptan at a single oral dose (15, 30 or 60 mg/day) or placebo [49] . Tolvaptan at all doses significantly reduced PCWP and right atrial and pulmonary artery pressure. Additionally, tolvaptan significantly increased urine output in a dose-dependent manner, without changes in renal function.
Liver cirrhosis In a Japanese multicenter, open-label, doseranging study tolvaptan was orally administrated at titrated doses of 15, 30 or 60 mg once daily for 3 days to 18 liver cirrhosis patients with persistent ascites and/or lower limb edema despite receiving oral furosemide at 40 mg/day or higher [50] . Tolvaptan was found to dose-dependently decrease body weight (−1.6±0.9, −2.6±1.2 and −3.4± 2.1 kg) and abdominal circumference (-−.8 to −6.0 cm) and improve ascites and edema beginning from a dose of 15 mg, demonstrating a potent aquaretic effect.
Cirrhosis and SIADH The Study of Ascending Levels of Tolvaptan in Hyponatremia (SALT trial) assessed the effects of tolvaptan in patients with hyponatremia. A total of 448 patients with hyponatremia due to SIADH, CHF or cirrhosis were treated either with tolvaptan or placebo for 30 days [51] . Primary endpoints were changes in serum sodium concentration at 4 and 30 days of therapy. The administration of tolvaptan was associated with a marked and significant increase in the area under the concentration time profile of serum sodium at days 4 (p<0.001) and 30 (p<0.001) compared to placebo. The number of patients with normal serum sodium concentration at the end of therapy was markedly higher in the tolvaptan than in the placebo group (55 vs. 25%, respectively). The effect of the drug on serum sodium concentration was observed both in patients with mild and in those with severe hyponatremia.
In the SALTWATER trial, a multicenter, open-label extension of the SALT trial, 111 patients with hyponatremia received oral tolvaptan for a mean follow-up of 701 days. All patients had hyponatremia at randomization in the SALT study, and 85% continued to have hyponatremia at baseline when entering the SALTWATER study. The mean sodium level increased from 130.8 mmol/l at baseline to >135 mmol/l throughout the observation period. It was shown that long-term treatment with tolvaptan was safe and efficient. Hypernatremia (>145 mmol/l) and subsequent discontinuation of the treatment occurred in one patient. The most common adverse effects of tolvaptan were pollakisuria, thirst, fatigue, dry mouth, polydipsia and polyuria [52] .
Lixivaptan
Lixivaptan is a potent, orally active, non-peptide V 2 Rselective antagonist. Lixivaptan inhibits AVP binding to the V 1a R with a half maximal inhibitory concentration (IC 50 ) of 230 nM and to the V 2 R with an IC 50 of 1.2±0.1 nM [53] . Lixivaptan also has a higher affinity for the V 2 R than other AVP receptor antagonists, as demonstrated in human and rat studies [53, 54] . Lixivaptan is currently undergoing Phase III clinical trials to determine its possible role in the treatment of hyponatremia associated with CHF, cirrhosis and SIADH. The dosage used in clinical trials carried out to date have ranged from 10 mg/day to a maximal daily dose of 400 mg/day.
The major side effects were reported at higher doses (>200 mg/day) and included excessive thirst, hypotension, hypernatremia and dehydration.
CHF The therapeutic potential of different doses of lixivaptan was evaluated in 42 patients with mild-tomoderate CHF (NYHA II/III) in a randomized, doubleblind, placebo-controlled, single-dose study [55] . Lixivaptan caused a significant and dose-dependent increase in urine volume and solute-free water excretion at all doses except the 10 mg dose. At doses >75 mg, serum sodium was significantly increased within the normal range. During a 24-h period, increases in urine volume ranged from 1.8 l with placebo to 3.9 l after administration of the 400 mg lixivaptan dose (p<0.01). Furthermore, no neurohormonal changes or any serious adverse events were reported during the use of lixivaptan. Unfortunately, clinical outcomes, such as dyspnea or global clinical status, were not assessed in this study.
In February 2008, a Phase III study known as the BALANCE trial (Treatment of Hyponatremia BAsed on LixivAptan in NYHA class III/IV Cardiac patient Evaluation) was initiated. The purpose of this ongoing multicenter, randomized, placebo-controlled, double-blind study is to determine the safety and efficacy of lixivaptan in the treatment of hyponatremia in 650 patients with worsening CHF. When available, the results of this trial should provide more insights into lixivaptan's potential for treating CHF patients [56] .
Liver cirrhosis/SIADH The effect of lixivaptan has also been investigated in liver cirrhosis. A randomized double-blind multicenter trial assigned 60 patients with liver cirrhosis and dilutional hyponatremia to 100 or 200 mg/day of lixivaptan or placebo [57] . Normalization of serum sodium concentration was achieved in 27 and 50% of patients in the lixivaptan 100 mg/day and 200 mg/day groups, respectively, but in none of the patients in the placebo group. The treatment was also associated with a significant reduction in urine osmolality and body weight.
Another randomized, double-blind, placebo-controlled trial investigated the pharmacodynamic effects of lixivaptan at different doses in cirrhotic patients with ascites [58] . Here again, lixivaptan produced a significant dose-related increase in daily urine output and a dose-related decrease in urine osmolality.
Data for the efficacy of lixivaptan in the treatment of SIADH have been obtained mostly in studies that included patients with liver cirrhosis and/or CHF, such as the study by Wong et al., who investigated the effect of lixivaptan at three different doses (25, 125 and 250 mg) given twice daily or placebo in patients with cirrhosis (n=33), CHF (n=6) or SIADH (n=5) [59] . Lixivaptan produced a significant overall aquaretic response compared with placebo, with significant dose-related increases in free water clearance (p<0.05) and serum sodium (p <0.05), without significant changes in orthostatic blood pressure or serum creatinine levels.
Another smaller study looking at the evolution hyponatremia in SIADH and liver cirrhosis after treatment with lixivaptan was conducted by Decaux [60] . Here, six hyponatremic patients with SIADH and five hyponatremic patients with cirrhosis and ascites were treated with 50 or 100 mg lixivaptan twice daily. In patients with SIADH treated with lixivaptan, serum sodium concentration was generally corrected within 1 day (126±4.5 mmol/l at 0 h and 133±5.6 mmol/l at 24 h) and associated with a decrease in sodium excretion (from 82±22 to 45±21 mmol/24 h; p<0.05) without any modification of potassium excretion, suggesting that lixivaptan is a highly effective drug in the short-term management of hyponatremic patients with SIADH.
Satavaptan
Satavaptan is an AVP receptor antagonist with an enhanced affinity to V 2 R compared to V 1a R [61, 62] . Thus, satavaptan inhibits AVP binding to the human V 2 R with a K I of 4.1±0.8 nM; the respective K I for V 1a R and V 1b R are 460±120 and >10.000 nM [63] . Satavaptan was intended to be used for the treatment of euvolemic and hypervolemic hyponatremia and was therefore under regulatory review in the European Union. However, the application for a centralized marketing authorization for satavaptan 5 mg and 25 mg was withdrawn by the developing company in May 2008, likely due to poorer survival in the satavaptantreated patients in a SPARe-1 trial (results have not been published to date).
Maximal plasma concentrations of the substance were observed 3 h after administration; mean plasma concentration increased with dosage and duration of drug application and stabilized on day 5. The major route of excretion was via feces [62] . Satavaptan is available as an oral preparation at 5-50 mg dosages; the aquaretic effect following drug administration persists up to 12 h [64] .
The efficacy of satavaptan was first evaluated in a Phase II trial in patients with hyponatremia due to SIADH [65] . Satavaptan was well tolerated in the clinical trials, with the main adverse effects associated with the use of satavaptan including increased thirst and dry mouth.
CHF Although satavaptan has demonstrated utility in animal models and improved clinical outcomes in patients with SIADH or cirrhosis [65] [66] [67] [68] , its efficacy in CHF patients has yet to be determined.
Liver cirrhosis In a randomized double-blind study of 150 cirrhotic patients with recurrent ascites with or without hyponatremia, satavaptan showed the potential to reduce the recurrence of ascites after large volume paracentesis [69] . In this study, three different doses of satavaptan (5, 12.5, and 25 mg/day) and a placebo were given to hypo-or normonatremic cirrhotic patients with ascites, who periodically required large volume paracentesis. All subjects also received spironolactone (100 mg/day). The main endpoints of the study were the length of the interval between two consecutive paracentesis procedures and the weekly amount of ascites accumulation estimated by summing up the liters of ascites removed with paracentesis and by following the changes in kilograms of body weight. A secondary endpoint was the total number of paracentesis procedures performed during 12 weeks of treatment. The trial was based on the rationale that increasing the urine volume by antagonizing the renal AVP effects can delay the recurrence of ascites after paracentesis. Indeed, satavaptan significantly (p<0.05) reduced the frequency of large volume paracentesis over a 3-month period in cirrhotic patients with recurrent ascites and was well tolerated. The mean increase in ascites was 2.82±0.48 l/week for placebo versus 2.12±0.40, 2.14± 0.33 and 2.06±0.40 l/week for 5, 12.5 and 25 mg satavaptan, respectively (p = NS for all doses).
The clinical applicability of satavaptan in the case of liver cirrhosis with hyponatremia was further assessed in the shortterm HypoCATtrial [67] . The multicenter, double-blind, randomized, controlled study compared three fixed doses of satavaptan (5, 12.5 or 25 mg once daily) versus placebo in 110 patients with cirrhosis, and hyponatremia (serum sodium≤130 mmol/l). Duration of treatment was 14 days, and all patients received spironolactone at 100 mg/day. Satavaptan treatment was associated with improved control of ascites, as indicated by a reduction in body weight and a parallel reduction in abdominal girth. This beneficial effect on ascites was associated with improvements in serum sodium (mean change from baseline to day 5 was 1.3±4.2, 4.5±3.5, 4.5±4.8 and 6.6±4.3 mmol/l for placebo and satavaptan 5, 12.5 and 25 mg/day, respectively; p <0.01 for all doses compared to placebo).
Thirst was significantly more common in patients treated with satavaptan than in those treated with placebo, whereas the frequency of other adverse events was similar among groups.
SIADH In the first part of a randomized, double-blind and placebo-controlled study, Soupart et al. studied the effect of satavaptan in 34 patients with hyponatremia due to SIADH [65] . The substance was shown to be effective in increasing serum sodium in 79% patients receiving 25 mg dose and 83% of patients treated with 50 mg substance in comparison to 13% of patients treated with placebo. Satavaptan also efficiently maintained serum sodium levels without serious adverse events during the long-term treatment in the following open label trial, suggesting that satavaptan adequately corrects mild or moderate hyponatremia in patients with SIADH.
In conclusion, satavaptan is a potent antagonist of renal AVP effects that, in combination with diuretics, might play a role in the treatment of recurrent or refractory ascites as well as in the correction of hyponatremia.
Combined V 1a /V 2 R antagonists
Conivaptan
Conivaptan is currently the only available dual V 1a /V 2 R antagonist with in vitro binding affinities (K I ) of 6.30 and 1.10 nmol/l for human V 1a R and V 2 R, respectively [70] .
Conivaptan is available for intravenous (i.v.) administration and was the first AVP receptor antagonist to be approved by the Federal Drug Administration (FDA) for treatment of euvolemic hyponatraemia; since 2007, conivaptan is also approved for hypervolemic hyponatraemia. At the present time, however, conivaptan is not indicated for primary treatment of CHF. Conivaptan is approved for use in hospitalized patients at an initial loading dose of 20 mg i.v. over 30 min, followed by 20 mg (max. 40 mg) continuous infusion over the next 24 h. The duration of continuous treatment should not exceed 4 days.
Conivaptan is metabolized by CYP3A4 [71] . Due to its interaction with CYP3A4, the coadministration of conivaptan with potent CYP3A4 inhibitors, such as clarithromycin, itraconazol, ketoconazole and ritonavir, is contraindicated. Approximately 83% of the agent is excreted in the feces and 12% in the urine [71, 72] . Conivaptan has been generally well tolerated in clinical trials, with the most reported adverse side effects being local injection site reactions, headache and thirst. Caution should be exercised in patients with renal or liver impairment.
Because of its dual V 1a /V 2 R antagonism, on a pharmacological basis, conivaptan represents an excellent option for the treatment of CHF, which is supported by its efficacy in animal models of altered cardiac function and volume overload. Intravenous administration of conivaptan was shown to produce hemodynamic improvement and marked aquaresis in a canine model of CHF induced by rapid right ventricular pacing [73] .
However, despite these encouraging animal data, human clinical evidence remains inconsistent. In a double-blind and placebo-controlled study of 142 patients with advanced CHF, conivaptan (10, 20 or 40 mg i.v.) produced favorable hemodynamic and renal effects. Decreases in PCWP (-2.6± 0.7, -5.4±0.7 and -4.6±0.7 mmHg for placebo and 20 and 40 mg groups, respectively; p<0.05) and right atrial pressure (−2.0±0.4, −3.7±0.4 and −3.5±0.4 mmHg for placebo and 20 and 40 mg groups, respectively; p<0.05) were accompanied by substantial increases in urine output (−11±17, 68± 17, 152±19 and 176±18 ml/h for placebo and 10, 20 and 40 mg groups, respectively; p<0.001), without affecting cardiac index, systemic and pulmonary vascular resistance, blood pressure, heart rate or serum electrolytes [74] . In the double-blind, placebo-controlled ADVANCE (A Dose evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) study, the effect of 12-week conivaptan treatment (10, 20 and 40 mg/day) was assessed in 343 patients with moderate-to-severe CHF [75] . However, conivaptan treatment was not associated with a significant improvement in overall functional capacity, exercise tolerance and quality of life in these patients.
The potential therapeutic benefit of conivaptan in patients with CHF prompted another pilot study to evaluate the efficacy and safety of conivaptan (20 mg loading dose followed by 24-h continuous infusions of 40, 80 or 120 mg/day) in alleviating the signs and symptoms of congestion in patients with ADHF [76] . Conivaptan at each dosage increased urine output significantly more than placebo at 24 h (p≤0.02), with the difference averaging 1 -1.5 l. The decreases in body weight with conivaptan 40 and 80 mg/day ranged from 0.7 to 2 kg greater than those with placebo (p=non-significant) without any overall improvement of clinical status, and was well tolerated in patients with ADHF.
Despite being well tolerated and able to significantly increase urine output, the precise role of conivaptan in CHF remains to be defined. In this respect, it should be emphasized that FDA approval is still restricted to the treatment of euvolemic hyponatremia.
Liver cirrhosis In the case of liver cirrhosis, conivaptan has been mainly assessed in animal studies. One of these studies addressed the effect of conivaptan on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites [77] . In this case, cirrhotic rats treated with conivaptan no longer showed any hyponatremia or water retention.
SIADH There is paucity of reported clinical experience using conivaptan for the treatment of the SIADH. A recent single-center study conducted by Velez et al. assessed retrospectively the effect of intravenous conivaptan as an aquaretic in 18 patients with SIADH [78] . 67% patients reached the primary endpoint of the study, defined as an absolute increase of≥4 mmol/l sodium over baseline 24 h after the initiation of therapy. Additionally, all patients had at least a 3-mmol/l increase in serum sodium 24 h after therapy initiation (mean baseline serum sodium of 121.7±3.3 mmol/l versus 129.2±2.6 mmol/l at 24 h, p<0.001). This increase in serum sodium was sustained at 48 and 72 h (129.6 ± 2.4 and 130.5 ± 2.5 mmol/l, respectively; p<0.001). At the same time, urine osmolality decreased in all patients. Lower serum sodium, lower blood urea nitrogen and higher estimated glomerular filtration rate at baseline were significantly correlated with the magnitude of the absolute increase in serum sodium 24 h after the initiation of therapy, suggesting that these variables may also help predicting the magnitude of response to therapy.
Conclusions
In recent years, the efficacy and safety of vasopressinreceptor antagonists in water-retentive disorders, such as CHF, SIADH and liver cirrhosis have been tested in several randomized clinical trials.
CHF, liver cirrhosis and SIADH remain a major health concern. Existing therapeutic options only slow the progression of CHF or cirrhosis, thus warranting the search for novel therapeutic approaches. In both acute and chronic CHF as well as in liver cirrhosis and SIADH, plasma AVP levels are inappropriately high and correlate with poor outcome. AVP has adverse effects by increasing peripheral resistance via vasoconstrictor actions at the V 1a R and contributing to water retention through effects at the renal V 2 R. Based on the pathophysiologic mechanisms and experimental data, V 2 R and, in particular, combined V 1a /V 2 R antagonists offer an excellent therapeutic option in CHF by serving as aquaretics and improving hemodynamic parameters. Although data from animal models are promising, human clinical trials on AVP receptor antagonists have shown only modest benefits in patients with CHF. To date, no mortality or morbidity benefits have been demonstrated for AVP antagonists in congestive heart disease. In the case of liver cirrhosis and SIADH, long-term data on the efficacy and safety of vaptans are still missing.
Unanswered questions are whether AVP receptor antagonists are superior to existing therapies, whether they truly have effects beyond the correction of hyponatremia and what are the advantages or disadvantages of combined V 1a /V 2 R antagonism. Because data on long-term administration are still incomplete, these agents cannot yet be used routinely.
Therefore, more clinical evidence is needed to establish the role of vaptans in the treatment of CHF, liver cirrhosis and SIADH. Such information is essential to be able to evaluate the risk/benefit ratio for the chronic use of vaptans outside randomized clinical trials.
